Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 known ✓ | Q16539 | 1/20 | 0.46 |
| ▸ | HTR2A known ✓ | P28223 | 10/20 | 0.45 |
| ▸ | DRD3 known ✓ | P35462 | 8/20 | 0.45 |
| ▸ | HTR7 known ✓ | P34969 | 2/20 | 0.44 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1545681 | 0.99 | MAPK14 (0.47) | MAPK14HTR2ADRD3HTR7ACHE | |
| Hydrochloric Acid SCHEMBL604319 | 0.89 | NPC1 (0.43) | MAPK14HTR2ADRD3NPC1RAB9A | |
| SCHEMBL23175351 | 0.88 | HTR2A (0.50) | HTR2ADRD3HTR7ACHE | |
| SCHEMBL29688952 | 0.87 | HTR3A (0.41) | MAPK14HTR2ADRD3NPC1RAB9A | |
| SCHEMBL20134950 | 0.87 | HTR3A (0.41) | MAPK14HTR2ADRD3NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL15486032 | 0.83 | MAPK14 (0.48) | MAPK14ACHE | |
| Hydrochloric Acid SCHEMBL531052 | 0.83 | ACHE (0.60) | HTR2AHTR7ACHE | |
| SCHEMBL8559886 | 0.82 | HTR2A (0.47) | HTR2ADRD3HTR7ACHE | |
| SCHEMBL8237364 | 0.82 | MAPK14 (0.47) | MAPK14HTR2AHTR7ACHE | |
| SCHEMBL7966100 | 0.81 | MAPK14 (0.47) | MAPK14HTR2AHTR7ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115362151-B | Arylpiperidines as monoacylglycerol lipase modulators | 詹森药业有限公司 | 2025-02-11 | — | — | CN | disclosed |
| US-20240092781-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-03-21 | — | — | US | disclosed |
| US-11787798-B2 | Aryl piperidines as monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-17 | — | — | US | disclosed |
| EP-4126840-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | Janssen Pharmaceutica NV (BE) | 2023-02-08 | — | — | EP | disclosed |
| CN-115362151-A | Aryl piperidines as monoacylglycerol lipase modulators | 詹森药业有限公司 | 2022-11-18 | — | — | CN | disclosed |
| US-20220363679-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-17 | — | — | US | disclosed |
| WO-2021191384-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | WO | disclosed |
| US-20140350051-A1 | Dual Modulators Of 5HT2A and D3 Receptors | HOFFMAN-LA ROCHE INC. | 2014-11-27 | — | — | US | disclosed |
| US-8829029-B2 | Dual modulators of 5HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2014-09-09 | — | — | US | disclosed |
| EP-2183245-B1 | DUAL MODULATORS OF 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2014-07-09 | — | — | EP | disclosed |
| US-20070004695-A1 | THIENOISOXAZOLYL-AND THIENYLPYRRAZOLYL PHENOXY SUBSTITUTED PROPYL DERIVATIVES USEFUL AS D4 ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | US | disclosed |
| EP-0452850-A1 | 4-[3-(4-Oxothiazoldinyl)]butynylamines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-10-23 | — | — | EP | disclosed |
| US-5034392-A | Analgesics or hypotensive agents | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-07-23 | — | — | US | disclosed |
| EP-0080104-B1 | 3-(4-PIPERIDYL)-1,2-BENZISOXAZOLES, PROCESS FOR THE PREPARATION THEREOF, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1988-12-14 | — | — | EP | disclosed |
| US-4528376-A | 3-(4-Piperidyl)-1,2-benzisoxazoles | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1985-07-09 | — | — | US | disclosed |
| US-4469869-A | ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1984-09-04 | — | — | US | disclosed |
| US-4408054-A | ANALGESTICS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1983-10-04 | — | — | US | disclosed |
| US-4408053-A | ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1983-10-04 | — | — | US | disclosed |
| EP-0080104-A2 | 3-(4-Piperidyl)-1,2-benzisoxazoles, process for the preparation thereof, and a pharmaceutical composition comprising the same | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1983-06-01 | — | — | EP | disclosed |
| US-4355037-A | ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS (US) | 1982-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092781-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | MAPK14 4696/4885HTR2A 26/4885DRD3 145/4885 |
| US-20070004695-A1 | THIENOISOXAZOLYL-AND THIENYLPYRRAZOLYL PHENOXY SUBSTITUTED PROPYL DERIVATIVES USEFUL AS D4 ANTAGONISTS | DRD4, DRD2, SLC6A3 | MAPK14 4175/4885HTR2A 25/4885DRD3 7/4885 |
| US-11787798-B2 | Aryl piperidines as monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | MAPK14 4696/4885HTR2A 26/4885DRD3 145/4885 |
| US-20140350051-A1 | Dual Modulators Of 5HT2A and D3 Receptors | HTR2A, HTR3A, HTR1A | MAPK14 3880/4885HTR2A 1/4885DRD3 10/4885 |
| US-20220363679-A1 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | MAPK14 4696/4885HTR2A 26/4885DRD3 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.